Hadjimichael O C, Meigs J W, Falcier F W, Thompson W D, Flannery J T
J Natl Cancer Inst. 1984 Oct;73(4):831-4.
A cohort of 3,139 obstetric patients, who delivered children between 1946 and 1965, was followed retrospectively to assess the relationship between exposure to diethylstilbestrol [(DES) CAS: 56-53-1; alpha, alpha'-diethyl-4,4'-stilbenediol] or other estrogenic substances during pregnancy and subsequent cancer incidence. Among the 1,531 women exposed to DES, the relative risk (RR) for all cancers was 1.46 [95% confidence interval (CI), 1.07-2.00]. The RR for cancers of the breast, cervix, and ovary were 1.37 (adjusted), 1.40, and 2.83, respectively, but none of these estimates was statistically significant. For breast cancer an RR in excess of 2.28 can be excluded, with 95% CI for doses averaging 2,100 mg. Within the exposed group there was no evidence for a dose-response relationship.
对1946年至1965年间分娩的3139名产科患者进行了回顾性随访，以评估孕期接触己烯雌酚[（DES）化学物质登记号：56-53-1；α，α'-二乙基-4,4'-二羟基二苯乙烯]或其他雌激素物质与随后癌症发病率之间的关系。在1531名接触DES的女性中，所有癌症的相对风险（RR）为1.46[95%置信区间（CI），1.07 - 2.00]。乳腺癌、宫颈癌和卵巢癌的RR分别为1.37（校正后）、1.40和2.83，但这些估计值均无统计学意义。对于乳腺癌，平均剂量为2100毫克时，可排除RR超过2.28的情况，95%CI为该剂量范围。在暴露组中，没有证据表明存在剂量反应关系。
